Edition:
United Kingdom

Aceto Corp (ACET.OQ)

ACET.OQ on NASDAQ Stock Exchange Global Select Market

2.82USD
22 May 2018
Change (% chg)

$0.02 (+0.71%)
Prev Close
$2.80
Open
$2.80
Day's High
$2.82
Day's Low
$2.80
Volume
4,129
Avg. Vol
174,528
52-wk High
$17.10
52-wk Low
$2.22

Latest Key Developments (Source: Significant Developments)

ACETO Reports Q3 Loss Per Share Of $5.57
Thursday, 3 May 2018 

May 3 (Reuters) - ACETO Corp ::ACETO REPORTS FISCAL 2018 THIRD QUARTER RESULTS.Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.01.Q3 LOSS PER SHARE $5.57.Q3 SALES $186 MILLION VERSUS I/B/E/S VIEW $177.2 MILLION.Q3 EARNINGS PER SHARE VIEW $0.23 -- THOMSON REUTERS I/B/E/S.  Full Article

Aceto To Appeal U.S. Government Ruling Regarding Certain Lucid Pharma Contracts
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Aceto Corp ::ACETO TO APPEAL U.S. GOVERNMENT RULING REGARDING CERTAIN LUCID PHARMA CONTRACTS.ACETO CORP - ‍NOTIFIED BY U.S. GOVERNMENT THAT 11 GENERIC DRUG PRODUCTS IT ACQUIRED ARE NOT IN COMPLIANCE WITH FEDERAL TRADE AGREEMENT ACT.ACETO-IF ‍SUPPLY CONTRACTS WITH U.S. DEPARTMENT OF VETERANS AFFAIRS ARE TERMINATED,CO DO NOT BELIEVE FINANCIAL IMPACT TO 2018 ADJUSTED EPS WILL BE MATERIAL ​.ACETO - ‍GENERIC DRUG PRODUCTS ACQUIRED THROUGH ACETRIS HEALTH UNIT WITH AN ENTITY FORMERLY KNOWN AS LUCID PHARMA ‍NOT IN COMPLIANCE WITH FEDERAL TAA​.ACETO CORP - ‍U.S. DEPARTMENT OF VETERANS AFFAIRS REQUESTED THAT ACETO SUPPLY NEW TAA-COMPLIANT SOURCES FOR REFERENCED PRODUCTS BY MARCH 9, 2018​.ACETO CORP - ‍U.S. DEPARTMENT OF VA REQUESTED THAT ACETO SUPPLY NEW TAA-COMPLIANT DRUGS TO GOVERNMENT PURCHASERS UNDER CONTRACTS BY MARCH 26, 2018.  Full Article

Aceto Appoints Edward Borkowski Chief Financial Officer
Friday, 16 Feb 2018 

Feb 16 (Reuters) - Aceto Corp ::ACETO APPOINTS EDWARD J. BORKOWSKI CHIEF FINANCIAL OFFICER.ACETO CORP - APPOINTS EDWARD BORKOWSKI AS CFO EFFECTIVE FEB 21, 2018.  Full Article

Aceto Q2 Loss Per Share $0.39
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Aceto Corp ::ACETO REPORTS FISCAL 2018 SECOND QUARTER RESULTS.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.22.Q2 LOSS PER SHARE $0.39.Q2 SALES ROSE 36.4 PERCENT TO $171.2 MILLION.SEES FY 2018 NON-GAAP EARNINGS PER SHARE $1.00 TO $1.05.IN QUARTER, NET LOSS INCLUDES $13.9 MILLION OF ADDITIONAL INCOME TAX EXPENSE ASSOCIATED WITH TAX CUTS AND JOBS ACT.SEES 2018 ‍TOTAL REVENUES TO INCREASE APPROXIMATELY 10% TO 15%​.SEES FY 2018 GAAP LOSS PER SHARE BETWEEN $0.22 AND $0.32."AS WE LOOK TO SECOND HALF OF FISCAL 2018, OUR OPERATING ASSUMPTION IS GENERIC INDUSTRY HEADWINDS WILL NOT EASE IN NEAR TERM".EXPECT OVERALL RESULTS FOR SECOND HALF OF YEAR TO BE "ONLY MODESTLY BETTER THAN FIRST HALF".2018 ‍REPORTED DILUTED GAAP LOSS PER SHARE INCLUDES AN ADDITIONAL TAX EXPENSE OF $0.39 RELATED TO TCJA​.IN 2018, SEES TOTAL GENERIC PRODUCT LAUNCHES OF 15 TO 20.  Full Article

Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES EFAVIRENZ CAPSULES, 50MG AND 200MG.SAYS UNIT ‍LAUNCHED GENERIC FOR EFAVIRENZ CAPSULES, AN FDA-APPROVED GENERIC VERSION OF REFERENCE LISTED DRUG SUSTIVA FROM BRISTOL MYERS SQUIBB​.  Full Article

Aceto reports fiscal 2018 first quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Aceto Corp :Aceto reports fiscal 2018 first quarter results.Q1 adjusted non-GAAP earnings per share $0.30.Q1 earnings per share $0.01.Q1 sales $185.3 million versus I/B/E/S view $190.6 million.Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S.Sees FY 2018 non-GAAP earnings per share $1.05 to $1.15.Aceto Corp sees ‍fiscal 2018 total revenues to increase approximately 15% to 20%​.Aceto Corp sees ‍fiscal 2018 reported diluted GAAP earnings per share between $0.23 and $0.33​.  Full Article

Aceto corp CFO Douglas Roth notifies co he will retire effective March 31, 2018​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Aceto Corp ::Says on October 26, Douglas Roth, Chief Financial Officer of Aceto Corporation notified company that he will retire effective March 31, 2018​.  Full Article

Aceto Q4 EPS $0.06
Thursday, 24 Aug 2017 

Aug 24 (Reuters) - Aceto Corp ::Q4 revenue $194.6 million.Aceto reports fiscal 2017 fourth quarter and full year results.Q4 adjusted Non-GAAP earnings per share $0.27.Q4 earnings per share $0.06.Q4 earnings per share view $0.44 -- Thomson Reuters I/B/E/S.Sees FY 2018 Non-GAAP earnings per share $1.25 to $1.40.Q4 revenue view $184.5 million -- Thomson Reuters I/B/E/S.Sees ‍fiscal 2018 total revenues to increase approximately 20% to 25%​.Sees ‍reported diluted GAAP earnings per share to increase to between $0.55 and $0.70 for fiscal 2018 ​.Sees fiscal 2018 research and development expense of $10 to $13 million.Sees FY2018 total generic product launches of 15 to 20.FY2017 earnings per share view $1.36, revenue view $628.2 million -- Thomson Reuters I/B/E/S.  Full Article

ACETO reports Q3 earnings per share $0.16
Thursday, 4 May 2017 

May 4 (Reuters) - ACETO Corp :Aceto reports fiscal 2017 third quarter results.Q3 adjusted non-gaap earnings per share $0.39.Q3 earnings per share $0.16.Q3 sales $190.1 million versus i/b/e/s view $195.1 million.Q3 earnings per share view $0.44 -- Thomson Reuters I/B/E/S.  Full Article

Aceto's unit launches Capecitabine Tablets, 150 & 500 MG
Tuesday, 28 Mar 2017 

Aceto Corp :Unit, Rising Pharmaceuticals launched Capecitabine tablets, 150 & 500 MG, AB-rated generic version of Xeloda tablets from Hoffman La Roche.  Full Article

BRIEF-ACETO Reports Q3 Loss Per Share Of $5.57

* Q3 EARNINGS PER SHARE VIEW $0.23 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)